# Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)

> **NCT04963088** · PHASE1,PHASE2 · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 65 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** BGB-A317
- **DRUG:** Anlotinib
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04963088
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-06
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-03-20
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04963088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04963088, "Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04963088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*